1-64841536-G-A
Variant names: 
Variant summary
Our verdict is Benign. The variant received -11 ACMG points: 0P and 11B. BP4_StrongBP6_ModerateBP7BS2
The NM_002227.4(JAK1):c.2469C>T(p.Leu823Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000929 in 1,614,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).
Frequency
 Genomes: 𝑓 0.000013   (  0   hom.,  cov: 32) 
 Exomes 𝑓:  0.0000089   (  0   hom.  ) 
Consequence
 JAK1
NM_002227.4 synonymous
NM_002227.4 synonymous
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -2.68  
Publications
2 publications found 
Genes affected
 JAK1  (HGNC:6190):  (Janus kinase 1) This gene encodes a membrane protein that is a member of a class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The encoded kinase phosphorylates STAT proteins (signal transducers and activators of transcription) and plays a key role in interferon-alpha/beta, interferon-gamma, and cytokine signal transduction. This gene plays a crucial role in effecting the expression of genes that mediate inflammation, epithelial remodeling, and metastatic cancer progression. This gene is a key component of the interleukin-6 (IL-6)/JAK1/STAT3 immune and inflammation response and is a therapeutic target for alleviating cytokine storms. The kinase activity of this gene is directly inhibited by the suppressor of cytokine signalling 1 (SOCS1) protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2020] 
JAK1 Gene-Disease associations (from GenCC):
- autoinflammation, immune dysregulation, and eosinophiliaInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -11 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.63). 
BP6
Variant 1-64841536-G-A is Benign according to our data. Variant chr1-64841536-G-A is described in ClinVar as Likely_benign. ClinVar VariationId is 134545.Status of the report is criteria_provided_single_submitter, 1 stars. 
BP7
Synonymous conserved (PhyloP=-2.68 with no splicing effect.
BS2
High AC in GnomAdExome4 at 13 AD gene. 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.0000131  AC: 2AN: 152158Hom.:  0  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
2
AN: 
152158
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.0000160  AC: 4AN: 249588 AF XY:  0.0000222   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
4
AN: 
249588
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.00000889  AC: 13AN: 1461874Hom.:  0  Cov.: 32 AF XY:  0.0000110  AC XY: 8AN XY: 727240 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
13
AN: 
1461874
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
8
AN XY: 
727240
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
33478
American (AMR) 
 AF: 
AC: 
12
AN: 
44724
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
26136
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
39700
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
86258
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
53420
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
5764
European-Non Finnish (NFE) 
 AF: 
AC: 
0
AN: 
1111998
Other (OTH) 
 AF: 
AC: 
1
AN: 
60396
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.467 
Heterozygous variant carriers
 0 
 1 
 2 
 3 
 4 
 5 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome   AF:  0.0000131  AC: 2AN: 152276Hom.:  0  Cov.: 32 AF XY:  0.0000269  AC XY: 2AN XY: 74452 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
2
AN: 
152276
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
2
AN XY: 
74452
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
41564
American (AMR) 
 AF: 
AC: 
2
AN: 
15296
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3472
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5180
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
4820
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10608
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
0
AN: 
68018
Other (OTH) 
 AF: 
AC: 
0
AN: 
2114
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.475 
Heterozygous variant carriers
 0 
 1 
 1 
 2 
 2 
 3 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
ClinVar
Significance: Likely benign 
Submissions summary: Benign:1Other:1 
Revision: criteria provided, single submitter
LINK: link 
Submissions by phenotype
not provided    Benign:1 
Oct 29, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not specified    Other:1 
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.